Recent

% | $
Quotes you view appear here for quick access.

TD Ameritrade Holding Corporation Message Board

news_to_use 50 posts  |  Last Activity: May 20, 2016 12:46 PM Member since: Jan 26, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Thank You to All Who Sold Me Shares Today

    by news_to_use May 19, 2016 11:44 AM
    news_to_use news_to_use May 20, 2016 12:46 PM Flag

    My posts keep getting eliminated. It gives them 5 times the revenue.

  • Reply to

    My avg cost is $1.3 but I will

    by straight_outta_luck May 19, 2016 12:43 PM
    news_to_use news_to_use May 20, 2016 12:15 PM Flag

    If you can't figure out that a stock going from 8 cents to 40 cents still means your investment became a 5 bagger in 6 days, then you don't belong in the stock market - you belong back in grade school. In actuality it was 4,5 times and I made mucho money there, just like I will here.

  • Reply to

    the Orexigen FUTURE

    by citi7trader May 18, 2016 12:54 PM
    news_to_use news_to_use May 19, 2016 7:16 PM Flag

    Sorry to correct but it gives them 5 times the revenue, not 4. OREX was only getting 20%, now they'll get 100%

  • Reply to

    My avg cost is $1.3 but I will

    by straight_outta_luck May 19, 2016 12:43 PM
    news_to_use news_to_use May 19, 2016 4:50 PM Flag

    At $1.30 it would only have a market cap around $180 including warrants. That is cheap, cheap, cheap. Look at worthless VVUS market cap. I would hold and make money if I were you. Remember what DRWI with similar short interest did - from $2.44 to $10.66 in 6 trading days - 450% gain - 6 trading days! Apr 6, 2016 9.24 10.66 8.59 8.80 3,743,300 8.80
    Apr 5, 2016 5.97 8.70 5.53 8.70 1,617,000 8.70
    Apr 4, 2016 5.66 6.15 5.23 5.92 490,500 5.92
    Apr 1, 2016 4.94 6.39 4.67 5.53 2,462,500 5.53
    Mar 31, 2016 3.29 4.99 3.29 4.93 841,200 4.93
    Mar 30, 2016 2.70 4.40 2.69 3.39 1,499,500 3.39
    Mar 29, 2016 2.31 2.50 2.30 2.44 16,200 2.44

  • Reply to

    Why did this Drop today?

    by news_to_use May 19, 2016 3:21 PM
    news_to_use news_to_use May 19, 2016 4:27 PM Flag

    I jumped into DRWI (which had about same short interest ) when the shorts got squeezed. It went from $2.44 to $10.66 in 6 trading days , a 450% jump in 6 days. Here's the move: Apr 6, 2016 9.24 10.66 8.59 8.80 3,743,300 8.80
    Apr 5, 2016 5.97 8.70 5.53 8.70 1,617,000 8.70
    Apr 4, 2016 5.66 6.15 5.23 5.92 490,500 5.92
    Apr 1, 2016 4.94 6.39 4.67 5.53 2,462,500 5.53
    Mar 31, 2016 3.29 4.99 3.29 4.93 841,200 4.93
    Mar 30, 2016 2.70 4.40 2.69 3.39 1,499,500 3.39
    Mar 29, 2016 2.31 2.50 2.30 2.44 16,200 2.44

  • Reply to

    Why did this Drop today?

    by news_to_use May 19, 2016 3:21 PM
    news_to_use news_to_use May 19, 2016 3:35 PM Flag

    This is what Wells analyst actually said (which I think is extremely poor reasoning):The payouts include a retention bonus of $1 million for each of three members and special equity awards valued between $1.25 million and $3.8 million.
    "We are surprised by these bonuses as we believe this opens the company up to criticism of being brazen in the face of public and government scrutiny for pricing practices," Maris wrote in a note. "It is not hard to see the criticism that the retention bonuses are being paid with money Valeant gained through excessive price increases and being paid to executives who in part helped oversee these pricing programs."

  • news_to_use by news_to_use May 19, 2016 3:21 PM Flag

    In addition to the general market, I really think it was related to VRX dropping so much. At one point they were both down about 10%, probably because uneducated retail longs and shorts (most likely more of these) perceive that if VRX gets too low iit will somehow fail and drop its European plans for OREX. I think they forgot to read the reason why VRX dropped today - it was because of bonuses! Here's the downgrade on VRX: Shares of Valeant ( VRX) are under pressure after Wells Fargo cut its estimates for the stock and repeated its underperform rating. According to Bloomberg, the move was prompted by Valeant's decision to pay out a fresh round of bonuses to its executives.

  • I won't state how many shares I now have, because no one would believe me. In a short time you people who sold will look back and ask yourself why you were so stupid. Your loss is my gain - I have seen you fools operate over and over again and still can't believe how stupid small retail investors and shortsellers are. It is no wonder that 85% of small traders go broke.. They actually think they known more than someone who has 22 million shares in a company and holds hundreds of millions of dollars. Such fools these mortals be! Thank you again from the bottom of my heart. Your gift is greatly appreciated!

  • Reply to

    Does anyone have a link to NAV

    by news_to_use May 18, 2016 5:50 PM
    news_to_use news_to_use May 18, 2016 5:53 PM Flag

    I should say I'm looking for current NAV (today) not EOY or previous quarter.

  • I can't find NAV on their site - can anyone give me a link to it.

  • Reply to

    Why would someone buy so many puts?

    by news_to_use May 18, 2016 5:28 PM
    news_to_use news_to_use May 18, 2016 5:36 PM Flag

    E-Commerce China DangDang releases quarterly results next week, and traders are positioning for a drop by the end of summer.

    optionMONSTER's monitoring system detected the purchase of 3,145 September 6 puts for $0.60 and $0.65 today. Volume was more than 11 times the open interest in the strike, showing that this is new positioning.

    Long puts lock in the price where a stock can be sold, so they make money if shares decline. Investors use them to hedge long positions or to speculate on a drop. (See our Education

  • You know they are going to come out with terrible earnings since they said conditions were bad with their offer and even if they had OK earnings, they will drive them way down to push their offer to be accepted. They certainly can't come out with good earnings after that offer! But it is all priced in here and their offer should keep the price around here. They are reporting on May 26, so we'll find out then.

  • news_to_use news_to_use May 17, 2016 5:58 PM Flag

    You are an idiot. I will actually exclude myself from the class action and go after them individually. People in the class action will get their $6.50 plus about 50 cents per share in the settlement.

  • Reply to

    What is OREX worth?

    by news_to_use May 17, 2016 1:15 PM
    news_to_use news_to_use May 17, 2016 4:38 PM Flag

    Milestones don't kick in until far from here. When they kick in shares will be worth 4X what I stated or $6 a share. They are going to greatly reduce CVOT price. It is only $30 mil per year as it currently stands. You won't be around 8 years from now (when it completes). Biotechs should trade at 3X revenue - has nothing to do with marketing expenses. All companies have them in all fields except ones that partner which then reduces revenue.

  • Reply to

    What is OREX worth?

    by news_to_use May 17, 2016 1:15 PM
    news_to_use news_to_use May 17, 2016 4:12 PM Flag

    They are only getting 20% of the revenue now. They get 100% in a few months. I am using figures from Takeda (Spencer Osborne has gone over these so I skipped the calculations). Europe is happening. VRX European division operates separate from US - Head of European operations said it is happening. I can't believe how uninformed you retail shorts are.

  • Since this is public Info, they will lose in court if they buy you out at $6.50 iMeigu made non-binding offer of $8.80 per ADR for Dangdang
    `Dangdang is cheap,' the Beijing-based investment firms says
    Share on Facebook
    Share on Twitter
    E-Commerce China Dangdang Inc., a Beijing-based online retailer, surged to a two-month high after receiving a competing bid to go private.
    The American depositary receipts advanced 7.9 percent to $7.13 at 2:44 p.m. in New York after iMeigu Capital Management said in a statement it will pay $8.80 in cash per Dangdang ADR. That’s 13 percent higher than an offer made by Chairman Peggy Yu Yu and Chief Executive Officer Guoqing Li in July. They own about 36 percent of the shares

  • Reply to

    What is OREX worth?

    by news_to_use May 17, 2016 1:15 PM
    news_to_use news_to_use May 17, 2016 1:43 PM Flag

    They have a year for share price to go over $1.

  • Drugmakers have been complaining about the difficulty of bringing new products to market in a regulatory climate that has become increasingly unpredictable and more likely to err on the side of safety in deciding risk/benefit ratios of experimental medicines.

    Data from this new study appears to bear that out.

    "It ain't getting any easier to develop new therapies." said Alan Eisenberg, head of emerging companies and business development for the biotech trade group Biotechnology Industry Organization (BIO), putting the findings succinctly.

    "Knowing more about the magnitude of risk can lead to smarter drug development as well as smarter investing," he said.

    The study, covering 2004 through 2010, found the overall success rate for drugs moving from early stage Phase I clinical trials to FDA approval is about one in 10, down from one in five to one in six seen in reports involving earlier years.

    The study, conducted by BIO and BioMedTracker, which collects data on drugs in development, reviewed more than 4,000 drugs from companies large and small and both publicly traded and private. It was released in conjunction with the annual BioCEO and Investor conference in New York.

    Adding weight to the desire by major pharmaceutical companies to become increasingly involved in biotechnology was a finding that biologics had a 15 percent chance of going from Phase I through to FDA approval, compared with a 7 percent success rate for traditional small molecule chemical drugs.

    When broken down by therapeutic categories, the highest overall success rate from Phase 1 through likelihood of approval was infectious diseases, such as hepatitis and HIV drugs, at 12 percent, followed by endocrine system drugs, featuring diabetes treatments, at 10.4 percent, and autoimmune diseases, such as rheumatoid arthritis, at 9.4 percent, the study found.

    John Craighead, BIO's managing director for investor relations, said clinical trial goals and the approval pathways for infectious diseases an

  • news_to_use by news_to_use May 17, 2016 1:15 PM Flag

    Small biotech companies usually trade at 3 times sales or more. OREX sales over the next year will be at least $70 million. (current sales are running around $64 million plus Korea and 18 European countries will add at bare minimum $6 mil). That means the market cap should be at $210 million or more. It is currently at $56 million. It should be roughly just under 4 times what it currently is, and the share price should be at least $1.53 right now. This stock is an absolute steal right here and you should be buying hand over fist.

  • Reply to

    OREX = NO Pipeline

    by icoltsi18 May 17, 2016 9:43 AM
    news_to_use news_to_use May 17, 2016 12:57 PM Flag

    85% of drugs in a pipeline fail before completing Phase III and 85% of small biotechs without any approved drug ultimately fail. I would much rather have a company with an approved drug that is just ready to be marketed to the world, then a company that is burning cash on its pipeline and will, in most probability, ultimately fail. Think about that 85% failure rate long and hard.

AMTD
32.47+0.56(+1.75%)May 27 4:00 PMEDT